Lilly to supply additional bamlanivimab and etesevimab to U.S. for Covid treatment, post-exposure prevention

  Eli Lilly and Company (NYSE: LLY) today announced an additional purchase by the U.S. government for bamlanivimab with etesevimab for administration together. This neutralizing antibody therapy is authorized for emergency use for the treatment of mild to moderate COVID-19 or for post-exposure prophylaxis of COVID-19 in certain individuals. As part of the agreement, Lilly will supply 614,000 doses of bamlanivimab with etesevimab no later than January 31, 2022 for a total of $1.29 billion. A minimum of 400,000 doses will be supplied no later than December 31, 2021.

The estimated impact of the new purchase to the 2021 guidance provided in Lilly's earnings release dated October 26, 2021 is $840 million of additional revenue and approximately 25 cents of additional earnings per share. The expected impact in 2022 will be reflected in the company's financial guidance to be provided in December 2021. 

http://kokomoperspective.com/politics/indiana/lilly-to-supply-614-000-additional-doses-of-bamlanivimab-and-etesevimab-to-the-u-s/article_789b1213-a2bf-5889-a045-49abc5ac195b.html